• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓瘤干细胞的两种状态。

Two States of Myeloma Stem Cells.

作者信息

Yaccoby Shmuel

机构信息

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.

出版信息

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):38-43. doi: 10.1016/j.clml.2017.09.020. Epub 2017 Oct 3.

DOI:10.1016/j.clml.2017.09.020
PMID:29066162
Abstract

The identity of so-called malignant stem cells in multiple myeloma has long been controversial. However, it is now appreciated that a small population of myeloma cells has a stem-like capacity for self-renewal and resides within the population of recognizable myeloma plasma cells, although whether these cells are quiescent or proliferative remains unresolved. It is also now accepted that subpopulations of myeloma plasma cells alternate bidirectionally and dynamically between immature and mature phenotypes, and both subpopulations are capable of clonogenicity in vitro and in animal models. Mounting evidence suggests that in multiple myeloma, small populations of quiescent myeloma stem cells behave as tumor-initiating cells as a result of their interaction with the endosteal bone marrow niche. However, a different, small population of proliferative myeloma stem cells produces the tumor bulk, and this population is likely responsible for the emergence of evolved subclones. A cellular-based plasticity model in which 2 states of stem-like cell compartments-quiescent and proliferative-exist simultaneously and are regulated dynamically by the microenvironment, epigenetics, and genetic aberrations may explain various clinical scenarios and the lack of consensus among some reported studies.

摘要

多发性骨髓瘤中所谓恶性干细胞的身份长期以来一直存在争议。然而,现在人们认识到,一小部分骨髓瘤细胞具有类似干细胞的自我更新能力,存在于可识别的骨髓瘤浆细胞群体中,尽管这些细胞是静止的还是增殖的仍未解决。现在也已公认,骨髓瘤浆细胞亚群在未成熟和成熟表型之间双向动态交替,并且这两个亚群在体外和动物模型中都具有克隆形成能力。越来越多的证据表明,在多发性骨髓瘤中,一小部分静止的骨髓瘤干细胞由于与骨内膜骨髓微环境相互作用而表现为肿瘤起始细胞。然而,另一小部分增殖性骨髓瘤干细胞产生肿瘤主体,并且这一群体可能是进化亚克隆出现的原因。一种基于细胞的可塑性模型,其中静止和增殖这两种干细胞样细胞区室状态同时存在,并由微环境、表观遗传学和基因畸变动态调节,这可能解释了各种临床情况以及一些报道研究之间缺乏共识的现象。

相似文献

1
Two States of Myeloma Stem Cells.骨髓瘤干细胞的两种状态。
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):38-43. doi: 10.1016/j.clml.2017.09.020. Epub 2017 Oct 3.
2
Fact or fiction--identifying the elusive multiple myeloma stem cell.事实还是虚构——识别难以捉摸的多发性骨髓瘤干细胞。
J Hematol Oncol. 2013 Dec 7;6:91. doi: 10.1186/1756-8722-6-91.
3
Concise review: Defining and targeting myeloma stem cell-like cells.简要综述:定义并靶向骨髓瘤干细胞样细胞。
Stem Cells. 2014 May;32(5):1067-73. doi: 10.1002/stem.1643.
4
Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.骨髓瘤干细胞概念、多发性骨髓瘤的异质性和可塑性。
Br J Haematol. 2013 Dec;163(5):551-64. doi: 10.1111/bjh.12563. Epub 2013 Sep 20.
5
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?癌症干细胞是多发性骨髓瘤耐药的原因:事实还是虚构?
Oncotarget. 2015 Dec 1;6(38):40496-506. doi: 10.18632/oncotarget.5800.
6
Endosteal and Perivascular Subniches in a 3D Bone Marrow Model for Multiple Myeloma.3D 骨髓模型中的骨内膜和血管周龛在多发性骨髓瘤中的作用。
Tissue Eng Part C Methods. 2018 May;24(5):300-312. doi: 10.1089/ten.TEC.2017.0467. Epub 2018 Apr 18.
7
The role of adhesion molecules in multiple myeloma.黏附分子在多发性骨髓瘤中的作用。
Acta Haematol. 1997;97(1-2):81-9. doi: 10.1159/000203663.
8
Cancer stem cells and the cellular hierarchy in haematological malignancies.癌症干细胞与血液恶性肿瘤中的细胞层级结构。
Eur J Cancer. 2009 Sep;45 Suppl 1:194-201. doi: 10.1016/S0959-8049(09)70033-4.
9
[Identification and targeting of multiple myeloma stem cells].[多发性骨髓瘤干细胞的鉴定与靶向治疗]
Nihon Rinsho. 2015 May;73(5):816-22.
10
Multiple myeloma cancer stem cells.多发性骨髓瘤癌干细胞。
Oncotarget. 2016 Jun 7;7(23):35466-77. doi: 10.18632/oncotarget.8154.

引用本文的文献

1
Interleukin-33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species-mediated inhibition of nuclear factor kappa-B signal and stemness properties.白细胞介素-33通过活性氧介导的核因子κB信号抑制和干性特性增加多发性骨髓瘤细胞对蛋白酶体抑制剂硼替佐米的敏感性。
MedComm (2020). 2024 May 9;5(5):e562. doi: 10.1002/mco2.562. eCollection 2024 May.
2
Identification of evolutionary mechanisms of myelomatous effusion by single-cell RNA sequencing.通过单细胞 RNA 测序鉴定骨髓瘤性渗出液的进化机制。
Blood Adv. 2023 Aug 8;7(15):4148-4159. doi: 10.1182/bloodadvances.2022009477.
3
Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.
恶性肿瘤前期和活动期骨髓瘤患者的 B 细胞淋巴生成的异质性。
JCI Insight. 2023 Feb 8;8(3):e159924. doi: 10.1172/jci.insight.159924.
4
Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.缺氧对多发性骨髓瘤发病机制和治疗耐药性的影响。
Cancer Sci. 2021 Oct;112(10):3995-4004. doi: 10.1111/cas.15087. Epub 2021 Aug 9.
5
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.新型肽-药物偶联物美法仑氟芬酰胺可有效根除硼替佐米耐药的多发性骨髓瘤细胞,包括肿瘤起始性骨髓瘤祖细胞。
Hemasphere. 2021 Jun 12;5(7):e602. doi: 10.1097/HS9.0000000000000602. eCollection 2021 Jul.
6
A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy.简明综述:干细胞在癌症进展与治疗中的作用
Onco Targets Ther. 2021 Apr 20;14:2761-2772. doi: 10.2147/OTT.S260391. eCollection 2021.
7
Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.选择性反义寡核苷酸抑制人 IRF4 通过细胞周期破坏防止恶性骨髓瘤再生。
Cell Stem Cell. 2021 Apr 1;28(4):623-636.e9. doi: 10.1016/j.stem.2020.12.017. Epub 2021 Jan 20.
8
The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond.CXCR4在多发性骨髓瘤中的作用:细胞从骨髓到其他部位的旅程。
J Bone Oncol. 2019 Jul 16;17:100253. doi: 10.1016/j.jbo.2019.100253. eCollection 2019 Aug.
9
Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s.由强制表达 XBP1s 驱动的小鼠多发性骨髓瘤祖细胞群体的定义。
JCI Insight. 2019 Apr 4;4(7). doi: 10.1172/jci.insight.124698.
10
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.抗 CD19 CAR T 细胞联合大剂量美法仑和自体干细胞移植治疗难治性多发性骨髓瘤。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.120505.